



20 August 2024

**Cambridge Cognition Holdings plc**  
("Cambridge Cognition", the "Company" or the "Group")

**Notice of Results**

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, will announce its unaudited interim results for the six months ended 30 June 2024 on Thursday 22 August 2024.

**Enquiries:**

**Cambridge Cognition Holdings plc**  
Matthew Stork, Chief Executive Officer

Tel: 012 2381 0700

**Panmure Liberum Limited (NOMAD and Joint Broker)**  
Will Goode / Freddy Crossley / Mark Rogers  
Rupert Dearden

Tel: 020 7886 2968  
(Corporate Finance)  
(Corporate Broking)

**Dowgate Capital Limited (Joint Broker)**  
David Poutney / James Serjeant

Tel: 020 3903 7715

**Hudson Sandler (Financial PR and IR)**  
Dan de Belder / Hattie Dreyfus

Tel: 020 7796 4133  
[cog@hudsonsandler.com](mailto:cog@hudsonsandler.com)

**Notes to Editors**

**About Cambridge Cognition**

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit: <https://cambridgecognition.com/>

RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORBCGDILBBDGSC